Serum levels of adiponectin and ghrelin in patients with acute myocardial infarction

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 523-526

  Hamed, Elham O ^a   Zaky, Nayel A ^a   Norel Din, Amal K ^a  

^a SOHAG UNIVERSITY   (Egypt)

Author keywords

Acute myocardial infarction; Adiponectin; Ghrelin

Indexed keywords

EID: 84874824533     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Aprahamian TR, Sam F. (2011): Adiponectin in Cardiovascular Inflammation and Obesity. Int J Inflam.; 2011:376909.
2. Cordido F, Isidro ML, Nemiña R, Sangiao-Alvarellos S. (2009): Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect. Curr Drug Discov Technol.; 6:34-42.
3. Fasshauer M, Kralisch S, Klier M, et al. (2003): Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications; 301(4):1045-1050.
4. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G, Kottas G. (2010a): Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease. Transl Res.; 155(5):238-46.
5. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. (2008) Novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrin Diab; 35:661-8.
6. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. (2010b): Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism; 59(3):373-9.
7. Kellokoski E, Kunnari A, Jokela M, Mäkelä S, Kesäniemi YA, Hörkkö S. (2009): Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidizedlow-density lipoprotein binding. Metabolism; 58:1572-80.
8. Kumada M, Kihara S, Sumitsuji S, et al. (2003): Association of hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis, Thrombosis and Vascular Biology; 23(1):85-89.
9. Maeda N, Takahashi M, Funahashi T, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes; 50(9):2094-2099.
10. Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P. (2010): Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. Journal of Internal Medicine; 268(2):194-205.
11. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. (1995): A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry; 270(45):26746-26749.
12. Shah A, Mehta N, Reilly MP. (2008): Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr.; 32:638-44.
13. Shibata R, Izumiya Y, Sato K, et al. (2007): Adiponectin protects against the development of systolic dysfunction following myocardial infarction. Journal of Molecular and Cellular Cardiology; 42(6):1065-1074.
14. Shibata R, Ouchi N, Ito M, et al. (2004): Adiponectinmediated modulation of hypertrophic signals in the heart. Nature Medicine; 10(12):1384-1389.
15. Shibata R, Sato K, Pimentel DR, et al. (2005): Adiponectin protects against myocardial ischemiareperfusion injury through AMPK-and COX-2-dependent mechanisms. Nature Medicine; 11(10):1096-1103.
16. Skilton MR, Celermajer DS. (2006): The effects of obesity related peptides on the vasculature. Curr Vasc Pharmacol; 4: 79-85.
17. Yano Y, Toshinai K, Inokuchi T, et al. (2009): Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis; 204:590-4.